Company Overview and News


Add BGNE
to your dashboard

Headline News

Week In Review: Sinocare Eyes $4 Billion Deal For J&J Diabetes Device Business

12h seekingalpha
Sinocare (SHZ:300298), a diabetes company based in Changsha, may bid as much as $4 billion to acquire Johnson & Johnson's (NYSE:JNJ) diabetes medical device subsidiaries (see story). With falling revenues, some of J&J's diabetes-focused companies are exiting from the US market because they can no longer compete and revenues are falling. Sinocare is backed by China Jianyin Investment (JIC), a unit of sovereign wealth fund China Investment Corp. (150-1)

ROTY Edition 1 Volume 71: Thoughts On A Juno Buyout, Outperformance Continues And Other Updates

2018-01-19 seekingalpha
A buyout of Juno Therapeutics would likely provide a boost to the biotech sector if it actually occurs. (372-0)

BeiGene (BGNE) Surges: Stock Moves 12.6% Higher

2018-01-19 zacks
BeiGene, Ltd. (BGNE - Free Report) was a big mover last session, as the company saw its shares rise nearly 13% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 20.9% in the past one-month time frame. (52-0)

Your Daily Pharma Scoop: Adamas's Gocovri, Onconova To Advance INSPIRE Study, Agios Initiates Public Offering

2018-01-19 seekingalpha
Today, we will Adamas Pharmaceuticals (ADMS) and the potential of company's Gocovri, which was approved by the FDA last year for the treatment of levodopa-induced dyskinesia in Parkinson's Disease (PD) patients. (210-1)

Your Daily Pharma Scoop: Adamas' Gocovri, Onconova To Advance INSPIRE Study, Agios Initiates Public Offering

2018-01-19 seekingalpha
Today we will Admas Pharmaceuticals' (ADMS) and the potential of company's Gocovri, which was approved by the FDA last year for the treatment of levodopa-induced dyskinesia in Parkinson's Disease (PD) patients. (210-0)

Investors Cheer BeiGene’s Secondary Offering

2018-01-18 247wallst
Shares of BeiGene Ltd. (NASDAQ: BGNE) saw a handy gain on Thursday after the company announced that it would be conducting a secondary offering. Usually, companies conducting these offerings see their shares drop to account for the dilution, but in this case investors are cheering the offering, sending shares even higher. (20-0)

Your Daily Pharma Scoop: Juno Surges On Takeover Rumors, AEterna Zentaris Achieves Another Milestone, Spark Granted ODD

2018-01-18 seekingalpha
Juno shares surged on WSJ report that Celgene is in talks to acquire the CAR-T company. (193-1)

Week In Review: Hua Medicine To Raise $200 Million Through Fundings And IPO For Oral Diabetes Drug

2018-01-14 seekingalpha
Hua Medicine of Shanghai expects to spend $200 million over the next three years on its novel oral diabetes 2 treatment, dorzagliatin. The company will raise additional capital for the effort and then IPO, possibly in Hong Kong or the US. The funds will underwrite Phase III development of its GKA product and commercialization. Ultimately, Hua hopes dorzagliatin will generate annual revenues of $3 billion, a 15% slice of the China type 2 diabetes market, once the drug is approved. (147-0)

Biotech Forum Daily Digest For January 10th

2018-01-10 seekingalpha
The biotech sector is failing to get any lift from the start of the big JP Morgan healthcare conference in San Francisco this week. (213-2)

ROTY Edition 1 Volume 69: BTD For Global Blood Therapeutics And Other Updates

2018-01-10 seekingalpha
After yesterday´s positive price action the ROTY model account is firmly in the green for the month of January (so far). (181-2)

Your Daily Pharma Scoop: Aradigm Sees Sell-Off Ahead Of Ad Com, Editas Provides Update, Axsome Suffers Setback

2018-01-10 seekingalpha
Today we will discuss the much-anticipated FDA briefing documents for Aradaigm’s (ARDM) Linhaliq. The documents were made available today ahead of the Ad Com meeting on Thursday, January 11th. (332-4)

Your Daily Pharma Scoop: Achaogen Is A Compelling Investment, Protalix Gains On Preliminary Results, BioTime Announces Publication Of Results

2018-01-03 seekingalpha
Today we will discuss the latest update from Achaogen (AKAO). AKAO shares surged in early trading on Tuesday after the clinical-stage biotech company moved a step closer to bringing its lead drug candidate, plazomicin, into the market. According to Blake Wise, Achaogen’s CEO, the number of confirmed cases of CRE annually in the U.S. alone total at least 70,000. More important, Wise noted is that the number is projected to double by 2022. (224-6)

Week In Review: Nearly $2 Billion Late-December Week For China Pharma Deals

2017-12-24 seekingalpha
Nanjing Legend Biotech received a $350 million upfront payment from Janssen Biotech, which will form a global partnership with Legend for its highly effective CAR-T candidate. In June, Legend, which was not previously well known, surprised the annual ASCO meeting with stunningly positive results from an early trial of the CAR-T molecule in patients with multiple myeloma. In addition to the $350 million initial payment, Janssen will make unspecified development and regulatory milestone payments to Legend. (455-3)

Jonathan Faison Positions For 2018: Faster FDA Approval, Emerging Sector In China Bode Well For Biotech Next Year

2017-12-20 seekingalpha
Despite recent doom and gloom talk that came as a result of the pullback in fall, it has still been a decent year. (482-1)

Blog Exposure - BeiGene Announced Initiation of Pivotal Trial of PARP Inhibitor Pamiparib in Chinese Patients with Ovarian Cancer

2017-12-20 accesswire
LONDON, UK / ACCESSWIRE / December 20, 2017 / Active-Investors issued a free report on BeiGene, Ltd. (NASDAQ: BGNE), which is readily accessible upon registration at www.active-investors.com/registration-sg/?symbol=BGNE as the Company's latest news hit the wire. On December 18, 2017, the biopharmaceutical Company declared that the first patient was dosed in a pivotal Phase-2 clinical trial evaluating investigational PARP inhibitor, pamiparib (BGB-290), in Chinese patients with advanced ovarian cancer who harbor a germline BRCA mutation. (13-0)

CUSIP: 07725L102